Patents Assigned to Biocytogen Pharmaceuticals (Beijing) Co., Ltd
  • Genetically modified non-human animals with humanized immunoglobulin locus
    Patent number: 11730151
    Abstract: The present disclosure relates to genetically modified animals and cells with humanized heavy chain immunoglobulin locus and/or humanized light chain immunoglobulin locus.
    Type: Grant
    Filed: October 12, 2022
    Date of Patent: August 22, 2023
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Jiawei Yao, Huizhen Zhao, Yabo Zhang, Lili Liu, Hui Lu, Shuwen Huang
  • Genetically modified mice expressing humanized CD47
    Patent number: 11723348
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD47, and methods of use thereof.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: August 15, 2023
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yang Bai, Jian Ni, Rui Huang, Chengzhang Shang, Yanan Guo
  • Genetically modified non-human animal with human or chimeric LAG3
    Patent number: 11564381
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) LAG3, and methods of use thereof.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: January 31, 2023
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Jiawei Yao, Chaoshe Guo, Yanan Guo, Yang Bai, Rui Huang, Lei Zhao, Meiling Zhang
  • Genetically modified non-human animal with human or chimeric TIGIT
    Patent number: 11534502
    Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric TIGIT (e.g., humanized TIGIT), and methods of use thereof.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: December 27, 2022
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yang Bai, Rui Huang, Yanan Guo, Xiaofei Zhou, Meiling Zhang
  • Genetically modified non-human animal with human or chimeric OX40
    Patent number: 11505806
    Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric OX40, and methods of use thereof.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: November 22, 2022
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Chaoshe Guo, Yang Bai, Jiawei Yao, Meiling Zhang, Xiaofei Zhou
  • Genetically modified mice expressing humanized CD40
    Patent number: 11497198
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD40, and methods of use thereof.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: November 15, 2022
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Chaoshe Guo, Rui Huang, Lei Zhao, Yanan Guo, Yang Bai, Meiling Zhang, Jiawei Yao
  • Genetically modified mouse comprising a chimeric TIGIT
    Patent number: 11464876
    Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric TIGIT (e.g., humanized TIGIT), and methods of use thereof.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: October 11, 2022
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yang Bai, Rui Huang, Yanan Guo, Xiaofei Zhou, Meiling Zhang
  • Humanized transgenic animal
    Patent number: 11439132
    Abstract: Provided are a humanized transgenic non-human animal, especially a rodent, in particular a transgenic mouse containing a human interleukin 17A (IL-17A) gene, a human gene 17RA (IL-17RA) and/or a human TNF-alpha gene, and a preparation method therefor and the use thereof.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: September 13, 2022
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Chaoshe Guo, Yanan Guo, Yang Bai, Rui Huang, Lei Zhao, Xiaofei Zhou, Meiling Zhang, Jiawei Yao
  • Anti-PD-1 antibodies and uses thereof
    Patent number: 11352429
    Abstract: This disclosure relates to anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: June 7, 2022
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yi Yang, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni, Yanan Guo, Yunyun Chen, Jingshu Xie
  • Genetically modified non-human animal with human or chimeric CD28
    Patent number: 11350614
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD28, and methods of use thereof.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: June 7, 2022
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yang Bai, Yanan Guo, Meiling Zhang, Rui Huang, Chengzhang Shang, Jiawei Yao
  • Genetically modified non-human animal with human or chimeric PD-L1
    Patent number: 11317611
    Abstract: Non-human animals, methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanized programmed death-ligand 1 (PD-L1, PDL1, or B7-H1). Such non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous PD-L1 gene so that the non-human animals express a humanized PD-L1 protein that includes a human portion and an endogenous portion (e.g., a non-human portion).
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: May 3, 2022
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yang Bai, Yanan Guo, Rui Huang, Xiaofei Zhou, Chaoshe Guo
  • Genetically modified non-human animal with human or chimeric OX40
    Patent number: 11279948
    Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric OX40, and methods of use thereof.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: March 22, 2022
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Chaoshe Guo, Yang Bai, Jiawei Yao, Meiling Zhang, Xiaofei Zhou
  • Genetically modified non-human animal with human or chimeric PD-1
    Patent number: 11272695
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) programmed cell death protein 1 (PD-1), and methods of use thereof. In one aspect, the animals have an insertion of a sequence encoding a human or humanized programmed cell death protein 1 (PD-1) at an endogenous PD-1 gene locus. This animal model can express a PD-1 protein containing a functional domain of the human PD-1 protein, and can be used as an animal model for developing therapeutics for human diseases and disorders, and assessing the toxicity and/or the efficacy of these human therapeutics.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: March 15, 2022
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yanan Guo, Yang Bai, Rui Huang, Xiaofei Zhou, Meiling Zhang, Jiawei Yao, Chaoshe Guo
  • Genetically modified non-human animal with human or chimeric TIM-3
    Patent number: 11240995
    Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric (e.g., humanized) T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and methods of use thereof.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: February 8, 2022
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Jian Ni, Yanan Guo, Rui Huang, Meiling Zhang, Lei Zhao, Yang Bai
  • Genetically modified non-human animal with human or chimeric IL15
    Patent number: 11234421
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL15, and methods of use thereof.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: February 1, 2022
    Assignees: Biocytogen JiangSu Co., Ltd., Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Meiling Zhang, Jiawei Yao, Chaoshe Guo, Yanan Guo, Yang Bai, Rui Huang, Lei Zhao
  • Method for constructing PD-1 gene modified humanized animal model and use thereof
    Patent number: 11234420
    Abstract: Provided is a method for preparing a PD-1 gene-modified humanized animal model. The method utilizes the CRIPSR/Cas9 technique to replace partial fragments of a mouse PD-1 gene with fragments of a human PD-1 gene using homologous recombination by constructing a targeting vector, thereby preparing a gene-modified humanized mouse. This mouse can normally express a PD-1 protein containing the functional domain of the human PD-1 protein, and can be used as an animal model for mechanism research regarding PD-1, PD-L1 and other signals, for screening regulators, and for toxicological research. The method has an important and high application value in studies on functions of the PD-1 gene and in the development of new drugs.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: February 1, 2022
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yang Bai, Rui Huang, Xiaofei Zhou, Yuting Hu, Yanan Guo, Jichao Du
  • Genetically modified non-human animal with human or chimeric CD137
    Patent number: 11154040
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD137, and methods of use thereof.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: October 26, 2021
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yanan Guo, Yang Bai, Lei Zhao, Rui Huang, Jiawei Yao, Meiling Zhang
  • Genetically modified non-human animal with human or chimeric genes
    Patent number: 11154041
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL4R and/or IL4, and methods of use thereof.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: October 26, 2021
    Assignees: Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Biocytogen JiangSu Co., Ltd.
    Inventors: Yuelei Shen, Yanan Guo, Yang Bai, Rui Huang, Xiaofei Zhou, Chengzhang Shang, Meiling Zhang, Jiawei Yao, Chaoshe Guo
  • Method of using a genetically modified mouse that expresses a humanized CTLA-4 gene
    Patent number: 11096383
    Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric CTLA-4, and methods of use thereof.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: August 24, 2021
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yanan Guo, Yang Bai, Jiawei Yao, Chengzhang Shang, Rui Huang
  • Genetically modified non-human animal with human or chimeric CTLA-4
    Patent number: 11071290
    Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric CTLA-4, and methods of use thereof.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: July 27, 2021
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yanan Guo, Yang Bai, Jiawei Yao, Chengzhang Shang, Rui Huang